• Merck   Medco Health Merck spreadsheet
  • Roy Vagelos and Louis Galambosh, Medicine, Science, and Merck
  • Raymond V Gilmartin: "The Worst Managers" Business Week (1/10/2005) | "Gilmartin: Merck Chief Exercises $34.8 Million In Options" Forbes (3/11/05) | "Merck CEO Goes On Defense, Cuts Jobs" Forbes (12/14/04) | Talk at Yale January 29, 2004 DSL/Cable/LAN
  • Major Products: Cozaar | Fosamax | Singulair | Vioxx [Vioxx Advisor / Vioxx Facts] | Zocor
  • Partners/Acquisitions: Actelion | Agilent | Banyu Pharmaceuticals | deCODE genetics | Exelixis | Neurogen | Orchid Cellmark | Par Pharmaceutical | Schering-Plough
• Top Competitors: Abbott Labs AstraZeneca Baxter Healthcare Bristol-Myers Squibb Eli Lilly GlaxoSmithKline Johnson & Johnson Novartis Pfizer Regeneron Sanofi-Aventis
• Industry Information: Albany College of Pharmacy Biology in Business BIO.COM BIO.ORG Canadian Pharmacy Online Contract Pharma fairdrugprices.org Pharmaceutical Research and Manufacturers of America / "What goes into the cost of prescription drugs?" (June 2005) Pharmalive
  • "Drug Stock ABCs Part 1" Fool.com (2/28/2007) "Licenses are low-cost, less risky than drug acquisitions" Money (323/2006) "More Bitter Pills For Big Pharma" Business Week (1/10/2005) "Pharma in Crisis" Forbes (3/13/06) "Selling The Promise Of Youth" Business Week (3/20/2006) "Stealing Share: Growing Market Share in the Pharmaceutical Industry" "The Best-Selling Drugs In America" Forbes (2/27/06)
• Medical Organizations: American Medical Association The Henry J. Kaiser Family Foundation
• Public Policy: Americans for Medical Progress  "Excess in the pharmaceutical industry" National Institutes of Health / National Center for Biotechnology Information U.S. Food and Drug Administration / Good Laboratory Practice Regulations (GLP) / NDAs Approved Universal Declaration of Human Rights - Healthy Documents World Health Organization WTO - Intellectual property: protection and enforcement
• "The Future of the Pharmaceutical Industry, According to Former Merck CEO Roy Vagelos" Knowledge@Wharton (April 17, 2006) "Merck extracts Medco thorn but still faces hurdles" Forbes (8/19/03) "Merck faces tough road after Vioxx, Fosamax setbacks" Money (1/28/2005) "Merck pulls Vioxx across the globe" MSNBC (9/30/2004) "Turning Merck Around -- Again" Business Week (3/26/04)
• Dogs of the Dow - Merck Fool.com: Merck in the Balance (1/27/04) | Merck’s Slow and Steady (2/25/04) | Merck’s Road to Recovery (3/2/2005) | Dueling Fools (6/23/2005) Forbes.com Merck Hoover’s Merck Yahoo! Finance Merck

Feedback to Paul Miesing    To go to Paul Miesing’s Page

Copyright � 2004 Paul Miesing. All rights reserved. Revised on December 12, 2008.